Medivation Founder Explains Why He Wants To Do Things Differently This Time

David Hung wants to do things differently at his new company.

Hung's the CEO of Axovant, a company that has a shot to launch the first new Alzheimer's drug in 15 years. Before joining the company in April, Hung founded Medivation, a cancer drugmaker based San Francisco that Pfizer bought for $14 billion in August 2016.

Back to news